The Centers for Medicare & Medicaid Services today proposed Medicare cover chimeric antigen receptor T-cell (CAR T) therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria. The proposed “coverage with evidence development” decision would require eligible patients receiving CAR T to be enrolled in a national registry or CMS-approved clinical study, and followed for at least two years to examine patient outcomes, clinical characteristics and health-related quality of life. The FDA in 2017 approved two CAR T-cell therapies for treating certain leukemias and lymphomas, which require safety monitoring through an FDA risk evaluation and mitigation strategy. The treatments are individually made by modifying the patient’s own T-cells, a type of white blood cell. CMS will accept comments on the proposed coverage decision through March 17. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services this week released final Medicare Advantage data on services provided to beneficiaries in calendar year 2015.
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The Centers for Medicare…
Headline
The Centers for Medicare…
Headline
The Centers for Medicare…
Headline
The Fund for Access to Inpatient Rehabilitation late yesterday announced that the government will settle backlogged Medicare inpatient rehabilitation facility…